| Code: MTA7181 | Publication Date: Aug 2025 |
For detailed forecasts, data tables, and competitive benchmarking,
Explore the full Global malaria vaccine market.
The market is gaining rapid traction with the rollout of WHO-approved malaria vaccines, especially in sub-Saharan Africa. Rising support from GAVI, UNICEF, and national immunization programs is accelerating distribution.
Key trends in the malaria vaccine market are emerging as staged roll-out plans evolve, companies increase their logistics and manufacturing capacities, and partnerships exist for cold chain distribution. Developers are also working on some promising multi-valent vaccines that will offer the opportunity to expand protection across variants of the parasite and across age groups.
New innovations in the Malaria Vaccine Market involve next-gen mRNA-based malaria vaccines, combination vaccines for co-infection, and alignment with current immunization schedules. Strong early progress in pilot countries will lead to plans for more global roll-out in partnership with coordinated efforts.
Below is a comprehensive list of the leading market players driving growth in this sector –
| Company Name | Moderna, Inc. |
|---|---|
| Established Year | 2010 |
| Headquarters | Cambridge, Massachusetts, United States |
| Official Website | Click Here |
Moderna is a biotechnology firm leveraging mRNA technology and is advancing a malaria vaccine candidate under development collaborations.
| Company Name | BioNTech SE |
|---|---|
| Established Year | 2008 |
| Headquarters | Mainz, Germany |
| Official Website | Click Here |
BioNTech, known for its mRNA expertise, is partnering on research to create innovative malaria vaccines targeting high-need regions.
| Company Name | Serum Institute of India |
|---|---|
| Established Year | 1966 |
| Headquarters | Pune, India |
| Official Website | Click Here |
This organization is one of the world’s largest vaccine manufacturers and is producing the R21/Matrix-M malaria vaccine for wide-scale deployment.
| Company Name | GSK plc |
|---|---|
| Established Year | 2000 |
| Headquarters | London, United Kingdom |
| Official Website | Click Here |
GSK is a global biopharmaceutical company that developed RTS, S/AS01, the first malaria vaccine recommended by WHO for widespread use.
| Company Name | Novavax, Inc. |
|---|---|
| Established Year | 1987 |
| Headquarters | Gaithersburg, Maryland, United States |
| Official Website | Click Here |
Novavax specializes in recombinant nanoparticle vaccines and is involved in developing next-generation malaria vaccines.
| Company Name | Sanaria Inc. |
|---|---|
| Established Year | 2003 |
| Headquarters | Rockville, Maryland, United States |
| Official Website | Click Here |
Sanaria focuses exclusively on malaria and is pioneering whole-parasite vaccine approaches, including its PfSPZ vaccine platform.
| Company Name | Oxford University’s Jenner Institute |
|---|---|
| Established Year | 2005 |
| Headquarters | Oxford, United Kingdom |
| Official Website | Click Here |
The Jenner Institute played a key role in developing the R21/Matrix-M vaccine, which shows high efficacy against malaria in clinical trials.
| Company Name | PATH (Program for Appropriate Technology in Health) |
|---|---|
| Established Year | 1977 |
| Headquarters | Seattle, Washington, United States |
| Official Website | Click Here |
PATH is a global nonprofit organization supporting malaria vaccine development, policy advocacy, and large-scale pilot implementations.
| Company Name | Infectious Disease Research Institute (IDRI) |
|---|---|
| Established Year | 1993 |
| Headquarters | Seattle, Washington, United States |
| Official Website | - |
IDRI is engaged in innovative vaccine research, including adjuvants and delivery systems to support malaria immunization solutions.
| Company Name | Bharat Biotech |
|---|---|
| Established Year | 1996 |
| Headquarters | Hyderabad, India |
| Official Website | Click Here |
Bharat Biotech is involved in the research and potential co-development of malaria vaccines for tropical regions, with a focus on scalable solutions.